Cystatin C, renal disease, amyloidosis and antibiotics
1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis- Promoting Proteins
- 2017
- Cystatin C as a Multifaceted Biomarker in Kidney Disease and Its Role in Defining "Shrunken Pore Syndrome"
- 2016
- Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting.
- 2015
- Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: 'Shrunken pore syndrome'.
- 2014
- Generation of a New Cystatin C-Based Estimating Equation for Glomerular Filtration Rate by Use of 7 Assays Standardized to the International Calibrator.
- 2013
- Stabilization, Characterization and Selective Removal of Cystatin C Amyloid Oligomers.
- 2003
- New antimicrobial cystatin C-based peptide active against gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus and multiresistant coagulase-negative staphylococci
- 1989
- Bacterial growth inhibited by a synthetic inhibitor based upon the structure of a human proteinase inhibitor
- 1987
- Immunohistochemical characterization of the amyloid deposits and quantitation of pertinent cerebrospinal fluid proteins in hereditary cerebral hemorrhage with amyloidosis
- 1985
- Serum Concentration of Cystatin C, Factor D and β2‐Microglobulin as a Measure of Glomerular Filtration Rate